NKGen completes acquisition of 65% stake in NKMax for ~$17M, gaining full control of manufacturing and IP

NKGen Biotech, Inc.

Acquired 46.4M shares at ~$0.36/share, representing 65% interest in NKMax out of bankruptcy.
Funding of ~$17M: majority from AlpineBrook Capital GP I Limited, remainder from CEO Paul Y. Song; terms pending.
Transaction grants NKGen full control of NKMax's global manufacturing infrastructure, IP, and exclusive commercialization rights.
NKGen expects to accelerate clinical development of troculeucel (Alzheimer's therapy) and expand NK cell therapy pipeline.
NKGen stock trades on OTC Expert Market; removal of parent overhang may renew investor interest.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.